Values as of: 2024-12-24
COMMON STOCK | Diagnostics & Research |
Last Closing
USD 45.06Change
+0.24 (+0.54)%Market Cap
USD 10.26BVolume
0.17MAnalyst Target
USD 52.64Verdict
Verdict
Qiagen N.V. offers sample to insight solutions that transform biological materials into molecular insights. The company provides sample technology consumables, such as nucleic stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID and forensics assay consumables, such as STR assays for human ID, and assays for food contamination; PCR instruments include digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It also offers predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a collaboration with the U.S. FBI; and with Bio-Manguinhos/Fiocruz to detect malaria and dengue. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Company Website : https://www.qiagen.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| DHR | Danaher Corporation |
+1.59 (+0.69%) |
USD 165.08B |
| A | Agilent Technologies Inc |
+1.50 (+1.11%) |
USD 40.09B |
| IQV | IQVIA Holdings Inc |
+0.88 (+0.44%) |
USD 36.13B |
| LH | Laboratory Corporation of Amer.. |
+1.65 (+0.72%) |
USD 19.12B |
| DGX | Quest Diagnostics Incorporated |
+0.48 (+0.31%) |
USD 17.09B |
| CRL | Charles River Laboratories |
+0.90 (+0.49%) |
USD 9.50B |
| VNRX | Volitionrx Ltd |
+0.04 (+6.56%) |
USD 0.06B |
| ENZ | Enzo Biochem Inc |
-0.01 (-1.90%) |
USD 0.04B |
| MTD | Mettler-Toledo International I.. |
+11.91 (+0.96%) |
N/A |
| TMO | Thermo Fisher Scientific Inc |
+3.69 (+0.70%) |
N/A |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|---|
| E908:XETRA | Lyxor 1 TecDAX (DR) UCITS.. | 7.91 % | 0.00 % |
N/A |
USD 0.09B |
| EXS2:XETRA | iShares TecDAX® UCITS ET.. | 7.88 % | 0.00 % |
N/A |
USD 0.77B |
| EXIB:XETRA | iShares TecDAX® UCITS ET.. | 7.88 % | 0.00 % |
N/A |
USD 0.77B |
| TDXPEX:SW | iShares TecDAX® UCITS ET.. | 7.88 % | 0.00 % |
N/A |
USD 5,933.97B |
| CB1TX:SW | Lyxor 1 TecDAX (DR) UCITS.. | 7.24 % | 0.00 % |
N/A |
N/A |
| CF1:PA | Amundi ETF MSCI France UC.. | 4.81 % | 0.00 % |
+0.85 (+0.00%) |
USD 9.67M |
| GNOM | Global X Genomics & Biote.. | 4.57 % | 0.00 % |
+0.05 (+0.00%) |
USD 0.07B |
| GNOG:LSE | Global X Genomics & Biote.. | 4.13 % | 0.00 % |
+0.03 (+0.00%) |
USD 9.08M |
| GN0M:XETRA | Global X Genomics & Biote.. | 4.05 % | 0.00 % |
N/A |
USD 7.05M |
| GNOM:SW | Global X Genomics & Biote.. | 4.05 % | 0.00 % |
N/A |
USD 9.83M |
| EDOC:SW | Global X Telemedicine & D.. | 4.03 % | 0.00 % |
N/A |
N/A |
| ZLI:CA | BMO Low Volatility Intern.. | 1.73 % | 0.42 % |
+0.02 (+0.00%) |
CAD 0.22B |
| IQQM:XETRA | iShares EURO STOXX Mid UC.. | 1.46 % | 0.00 % |
N/A |
USD 0.39B |
| DJMC:SW | iShares EURO STOXX Mid UC.. | 1.46 % | 0.00 % |
N/A |
USD 0.39B |
| MVAE:PA | 0.77 % | 0.00 % |
N/A |
N/A | |
| QRH:CA | 0.00 % | 1.20 % |
N/A |
N/A | |
| JPED | 0.00 % | 0.74 % |
N/A |
N/A | |
| E908:F | Lyxor 1 - TecDAX UCITS ET.. | 0.00 % | 0.00 % |
N/A |
N/A |
| EXS2:F | iShares TecDAX UCITS ETF .. | 0.00 % | 0.00 % |
N/A |
N/A |
| C007:XETRA | Amundi Index Solutions - .. | 0.00 % | 0.00 % |
N/A |
USD 0.16B |
| E907:XETRA | Lyxor 1 MDAX (DR) UCITS E.. | 0.00 % | 0.00 % |
N/A |
USD 0.13B |
| ELF1:XETRA | Deka MDAX® UCITS ETF | 0.00 % | 0.00 % |
N/A |
USD 0.35B |
| EXS3:XETRA | iShares MDAX® UCITS ETF .. | 0.00 % | 0.00 % |
N/A |
USD 1.12B |
| DEAM:XETRA | Invesco MDAX® UCITS ETF .. | 0.00 % | 0.00 % |
N/A |
USD 0.24B |
| Market Performance vs. Industry/Classification (Diagnostics & Research) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 3.75% | 85% | B | 50% | F | ||
| Dividend Return | 3.04% | 100% | F | 46% | F | ||
| Total Return | 6.79% | 85% | B | 46% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | 3.68% | 85% | B | 50% | F | ||
| Dividend Return | 3.04% | 100% | F | 46% | F | ||
| Total Return | 6.72% | 85% | B | 48% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | 36.92% | 42% | F | 69% | C- | ||
| Dividend Return | 4.01% | 60% | D- | 10% | F | ||
| Total Return | 40.93% | 42% | F | 63% | D | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 0.58% | 23% | F | 34% | F | ||
| Dividend Return | 1.14% | 23% | F | 27% | F | ||
| Total Return | 0.55% | 71% | C- | 14% | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 15.58% | 92% | A | 65% | D | ||
| Risk Adjusted Return | 7.29% | 23% | F | 25% | F | ||
| Market Capitalization | 10.26B | 44% | F | 86% | B+ | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.
The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
